Drug
Loncastuximab tesirine clinical trials
Also written Zynlonta, ADCT-402 and MT-2111.
Keep track of what changes. Save the loncastuximab tesirine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2022 (9)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 9 |
| 2023 | 8 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 20
ADC Therapeutics S.A. (10) · University of Utah (3) · University of Miami (2) · University of Alabama at Birmingham (1) · Medical College of Wisconsin (1) · University of California, Davis (1) · Fondazione Italiana Linfomi - ETS (1) · Tanabe Pharma Corporation (1)
Often tested with
Tested in the same studies.
Rituximab (7) · Epcoritamab (2) · Etoposide (2) · Acalabrutinib (1) · Venetoclax (1) · Mosunetuzumab (1) · Odronextamab (1) · Ifosfamide (1)
Studies
Open first, then newest update. How each study uses loncastuximab tesirine is read from its arms, and is right about nine times in ten.
Testing it · 31
- Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)RecruitingPhase 2University of UtahNCT06788964Written as Loncastuximab Tesirine
- Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaRecruitingPhase 2University of MiamiNCT06919939Written as Loncastuximab Tesirine
- Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)Not yet recruitingPhase 1/2University of UtahNCT07573436Written as Loncastuximab tesirine
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT05672251Written as Loncastuximab Tesirine
- Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone LymphomaRecruitingPhase 2University of MiamiNCT05296070Written as Loncastuximab tesirine 150 µg/Kg
- Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)RecruitingPhase 1University of UtahNCT06607549Written as Loncastuximab tesirine and rituximab (Lonca-R)
- Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingPhase 2Universität MünsterNCT07197307Written as Loncastuximab Tesirine and Epcoritamab
- A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell TherapyRecruitingPhase 2M.D. Anderson Cancer CenterNCT05464719Written as Loncastuximab Tesirine
- Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaRecruitingPhase 2Juan P. Alderuccio, MDNCT04998669Written as Loncastuximab tesirine
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingPhase 2/3University of BirminghamNCT05991388Written as Loncastuximab tesirine
- Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy FailureRecruitingPhase 2Istituto Clinico HumanitasNCT06918912Written as Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
- Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaActive, not recruitingPhase 1University of Alabama at BirminghamNCT05971251Written as Loncastuximab Tesirine and Acalabrutinib
- Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesActive, not recruitingPhase 1Medical College of WisconsinNCT05270057Written as Loncastuximab Tesirine 0.075 mg/kg by IV
- Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaActive, not recruitingPhase 2University of California, DavisNCT05600686Written as Loncastuximab Tesirine
- Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.Active, not recruitingPhase 2Fondazione Italiana Linfomi - ETSNCT05249959Written as Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
- A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)TerminatedPhase 1ADC Therapeutics S.A.NCT05660395Written as Loncastuximab Tesirine
- Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesTerminatedPhase 2University of WashingtonNCT05453396Written as Loncastuximab Tesirine
- A Study of MT-2111 in Patients With Relapsed/Refractory DLBCLActive, not recruitingPhase 1/2Tanabe Pharma CorporationNCT05658562Written as MT-2111
- Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin LymphomaActive, not recruitingPhase 1Paolo Caimi, MDNCT05053659Written as Loncastuximab tesirine
- Loncastuximab Tesirine in WMActive, not recruitingPhase 2Shayna Sarosiek, MDNCT05190705Written as Loncastuximab Tesirine
See all 31 studies that test loncastuximab tesirine →
Given in every arm · 2 — loncastuximab tesirine is usual care beside what is tested
- A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesRecruitingPhase 1Janssen Research & Development, LLCNCT07308132Written as loncastuximab tesirine
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)Active, not recruitingPhase 1ADC Therapeutics S.A.NCT04970901Written as Loncastuximab Tesirine
Codes
What other systems call loncastuximab tesirine · ClinicalTrials.gg INT001429
- MeSH (NLM) C000710749loncastuximab tesirineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7K5O7P6QIULONCASTUXIMAB TESIRINEConfirmed FDA, NLM, Wikidata
- RxNorm 2540964One source FDA
- Wikidata Q39057117loncastuximab tesirineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C125549Loncastuximab TesirineOne source FDA
- DrugBank DB16222One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710749 | loncastuximab tesirine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7K5O7P6QIU | LONCASTUXIMAB TESIRINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2540964 | — | One source FDA |
| Wikidata | Q39057117 | loncastuximab tesirine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C125549 | Loncastuximab Tesirine | One source FDA |
| DrugBank | DB16222 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.